177 related articles for article (PubMed ID: 24297685)
1. Detection of a novel mutation in exon 20 of the BRCA1 gene.
Chakraborty A; Katarkar A; Chaudhuri K; Mukhopadhyay A; Basak J
Cell Mol Biol Lett; 2013 Dec; 18(4):631-8. PubMed ID: 24297685
[TBL] [Abstract][Full Text] [Related]
2. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.
Shiozaki EN; Gu L; Yan N; Shi Y
Mol Cell; 2004 May; 14(3):405-12. PubMed ID: 15125843
[TBL] [Abstract][Full Text] [Related]
3. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.
Clapperton JA; Manke IA; Lowery DM; Ho T; Haire LF; Yaffe MB; Smerdon SJ
Nat Struct Mol Biol; 2004 Jun; 11(6):512-8. PubMed ID: 15133502
[TBL] [Abstract][Full Text] [Related]
4. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
5. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.
Varma AK; Brown RS; Birrane G; Ladias JA
Biochemistry; 2005 Aug; 44(33):10941-6. PubMed ID: 16101277
[TBL] [Abstract][Full Text] [Related]
8. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
Tischkowitz M; Hamel N; Carvalho MA; Birrane G; Soni A; van Beers EH; Joosse SA; Wong N; Novak D; Quenneville LA; Grist SA; ; Nederlof PM; Goldgar DE; Tavtigian SV; Monteiro AN; Ladias JA; Foulkes WD
Eur J Hum Genet; 2008 Jul; 16(7):820-32. PubMed ID: 18285836
[TBL] [Abstract][Full Text] [Related]
9. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.
Rodriguez M; Yu X; Chen J; Songyang Z
J Biol Chem; 2003 Dec; 278(52):52914-8. PubMed ID: 14578343
[TBL] [Abstract][Full Text] [Related]
10. High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1.
Lokesh GL; Rachamallu A; Kumar GD; Natarajan A
Anal Biochem; 2006 May; 352(1):135-41. PubMed ID: 16500609
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains.
Botuyan MV; Nominé Y; Yu X; Juranic N; Macura S; Chen J; Mer G
Structure; 2004 Jul; 12(7):1137-46. PubMed ID: 15242590
[TBL] [Abstract][Full Text] [Related]
13. BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1.
Dohrn L; Salles D; Siehler SY; Kaufmann J; Wiesmüller L
Biochem J; 2012 Feb; 441(3):919-26. PubMed ID: 22032289
[TBL] [Abstract][Full Text] [Related]
14. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1.
Cantor SB; Guillemette S
Future Oncol; 2011 Feb; 7(2):253-61. PubMed ID: 21345144
[TBL] [Abstract][Full Text] [Related]
15. The BRCA1 C-terminal domain: structure and function.
Huyton T; Bates PA; Zhang X; Sternberg MJ; Freemont PS
Mutat Res; 2000 Aug; 460(3-4):319-32. PubMed ID: 10946236
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations.
Nominé Y; Botuyan MV; Bajzer Z; Owen WG; Caride AJ; Wasielewski E; Mer G
Biochemistry; 2008 Sep; 47(37):9866-79. PubMed ID: 18717574
[TBL] [Abstract][Full Text] [Related]
17. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.
Williams RS; Glover JN
J Biol Chem; 2003 Jan; 278(4):2630-5. PubMed ID: 12427738
[TBL] [Abstract][Full Text] [Related]
18. Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.
Williams RS; Chasman DI; Hau DD; Hui B; Lau AY; Glover JN
J Biol Chem; 2003 Dec; 278(52):53007-16. PubMed ID: 14534301
[TBL] [Abstract][Full Text] [Related]
19. Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase.
Kumaraswamy E; Shiekhattar R
Mol Cell Biol; 2007 Oct; 27(19):6733-41. PubMed ID: 17664283
[TBL] [Abstract][Full Text] [Related]
20. BACH1 is a DNA repair protein supporting BRCA1 damage response.
Peng M; Litman R; Jin Z; Fong G; Cantor SB
Oncogene; 2006 Apr; 25(15):2245-53. PubMed ID: 16462773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
